These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27591436)

  • 1. Employing the promiscuity of lantibiotic biosynthetic machineries to produce novel antimicrobials.
    Montalbán-López M; van Heel AJ; Kuipers OP
    FEMS Microbiol Rev; 2017 Jan; 41(1):5-18. PubMed ID: 27591436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lantibiotics: promising candidates for future applications in health care.
    Dischinger J; Basi Chipalu S; Bierbaum G
    Int J Med Microbiol; 2014 Jan; 304(1):51-62. PubMed ID: 24210177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodologies and strategies for the bioengineering of lantibiotics.
    Nagao J; Nishie M; Sonomot K
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1221-30. PubMed ID: 21470152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lantibiotics: insight and foresight for new paradigm.
    Nagao J; Asaduzzaman SM; Aso Y; Okuda K; Nakayama J; Sonomoto K
    J Biosci Bioeng; 2006 Sep; 102(3):139-49. PubMed ID: 17046525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of lantibiotic biosynthetic machinery promiscuity and its impact on antimicrobial discovery.
    Sandiford SK
    Expert Opin Drug Discov; 2020 Mar; 15(3):373-382. PubMed ID: 31941374
    [No Abstract]   [Full Text] [Related]  

  • 6. Increasing the success rate of lantibiotic drug discovery by Synthetic Biology.
    Montalbán-López M; Zhou L; Buivydas A; van Heel AJ; Kuipers OP
    Expert Opin Drug Discov; 2012 Aug; 7(8):695-709. PubMed ID: 22680308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosynthesis and transport of the lantibiotic mutacin 1140 produced by Streptococcus mutans.
    Escano J; Stauffer B; Brennan J; Bullock M; Smith L
    J Bacteriol; 2015 Apr; 197(7):1173-84. PubMed ID: 25605307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lantibiotic engineering: molecular characterization and exploitation of lantibiotic-synthesizing enzymes for peptide engineering.
    Nagao J; Aso Y; Shioya K; Nakayama J; Sonomoto K
    J Mol Microbiol Biotechnol; 2007; 13(4):235-42. PubMed ID: 17827974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dawning of a 'Golden era' in lantibiotic bioengineering.
    Field D; Hill C; Cotter PD; Ross RP
    Mol Microbiol; 2010 Dec; 78(5):1077-87. PubMed ID: 21091497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lantibiotic production by pathogenic microorganisms.
    Daly KM; Cotter PD; Hill C; Ross RP
    Curr Protein Pept Sci; 2012 Sep; 13(6):509-23. PubMed ID: 22708496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roseocin, a novel two-component lantibiotic from an actinomycete.
    Singh M; Chaudhary S; Sareen D
    Mol Microbiol; 2020 Feb; 113(2):326-337. PubMed ID: 31696567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curvopeptin: a new lanthionine-containing class III lantibiotic and its co-substrate promiscuous synthetase.
    Krawczyk B; Völler GH; Völler J; Ensle P; Süssmuth RD
    Chembiochem; 2012 Sep; 13(14):2065-71. PubMed ID: 22907786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathermycin, a Lantibiotic from the Marine Actinomycete Marinactinospora thermotolerans SCSIO 00652.
    Chen E; Chen Q; Chen S; Xu B; Ju J; Wang H
    Appl Environ Microbiol; 2017 Aug; 83(15):. PubMed ID: 28576760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of new class III lantibiotics--erythreapeptin, avermipeptin and griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-terminal leader processing.
    Völler GH; Krawczyk JM; Pesic A; Krawczyk B; Nachtigall J; Süssmuth RD
    Chembiochem; 2012 May; 13(8):1174-83. PubMed ID: 22556031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioengineering of the model lantibiotic nisin.
    Field D; Cotter PD; Ross RP; Hill C
    Bioengineered; 2015; 6(4):187-92. PubMed ID: 25970137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence-based analysis and prediction of lantibiotics: A machine learning approach.
    Poorinmohammad N; Hamedi J; Moghaddam MHAM
    Comput Biol Chem; 2018 Dec; 77():199-206. PubMed ID: 30342319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics.
    Escano J; Stauffer B; Brennan J; Bullock M; Smith L
    Microbiologyopen; 2014 Dec; 3(6):961-72. PubMed ID: 25400246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering lanthipeptides by introducing a large variety of RiPP modifications to obtain new-to-nature bioactive peptides.
    Fu Y; Xu Y; Ruijne F; Kuipers OP
    FEMS Microbiol Rev; 2023 May; 47(3):. PubMed ID: 37096385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multipronged approach for engineering novel peptide analogues of existing lantibiotics.
    Escano J; Smith L
    Expert Opin Drug Discov; 2015; 10(8):857-70. PubMed ID: 26004576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.
    Repka LM; Chekan JR; Nair SK; van der Donk WA
    Chem Rev; 2017 Apr; 117(8):5457-5520. PubMed ID: 28135077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.